UY27897A1 - Derivados de piperidina novedosos - Google Patents

Derivados de piperidina novedosos

Info

Publication number
UY27897A1
UY27897A1 UY27897A UY27897A UY27897A1 UY 27897 A1 UY27897 A1 UY 27897A1 UY 27897 A UY27897 A UY 27897A UY 27897 A UY27897 A UY 27897A UY 27897 A1 UY27897 A1 UY 27897A1
Authority
UY
Uruguay
Prior art keywords
piperidine derivatives
new piperidine
new
ccl3
mip
Prior art date
Application number
UY27897A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Matthew Frank Brown
Matthew Merrill Hayward
Christopher Stanley Poss
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY27897A1 publication Critical patent/UY27897A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula en el que a,b,c,R1,R2,R3,R4,R5,R6,R7, Q,W,Y y Z son como se define anteriormente, útiles como inhibidores potentes y selectivos de la unión de MIP-1 a (CCL3) a su receptor CCR1 que se encuentra en las células inflamatorias e inmunomoduladoras (preferiblemente leucocitos y linfocitos.
UY27897A 2002-07-18 2003-07-16 Derivados de piperidina novedosos UY27897A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39710802P 2002-07-18 2002-07-18

Publications (1)

Publication Number Publication Date
UY27897A1 true UY27897A1 (es) 2004-02-27

Family

ID=30770997

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27897A UY27897A1 (es) 2002-07-18 2003-07-16 Derivados de piperidina novedosos

Country Status (24)

Country Link
US (1) US20040063759A1 (es)
EP (1) EP1534677A1 (es)
JP (1) JP2005537279A (es)
KR (1) KR20050021497A (es)
CN (1) CN1668592A (es)
AP (1) AP2005003200A0 (es)
AR (1) AR040583A1 (es)
AU (1) AU2003242941A1 (es)
BR (1) BR0312946A (es)
CA (1) CA2492651A1 (es)
EC (1) ECSP055547A (es)
HN (1) HN2003000222A (es)
IL (1) IL166010A0 (es)
IS (1) IS7614A (es)
MA (1) MA27326A1 (es)
MX (1) MXPA05000380A (es)
OA (1) OA12885A (es)
PA (1) PA8575901A1 (es)
PE (1) PE20040666A1 (es)
TN (1) TNSN05014A1 (es)
TW (1) TW200402416A (es)
UY (1) UY27897A1 (es)
WO (1) WO2004009550A1 (es)
ZA (1) ZA200500067B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399790B2 (en) 2001-02-28 2008-07-15 Konowalchuk Thomas W Virucidal compositions
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
DK1531822T3 (da) 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
AU2003281527A1 (en) * 2002-07-18 2004-02-09 Pfizer Products Inc. Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor
US8261062B2 (en) 2003-03-27 2012-09-04 Microsoft Corporation Non-cryptographic addressing
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CN1950082B (zh) 2004-03-03 2013-02-06 凯莫森特里克斯股份有限公司 双环和桥连的含氮杂环化物
US7929689B2 (en) 2004-06-30 2011-04-19 Microsoft Corporation Call signs
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
US7620902B2 (en) 2005-04-20 2009-11-17 Microsoft Corporation Collaboration spaces
US7617281B2 (en) 2005-04-25 2009-11-10 Microsoft Corporation System and method for collaboration with serverless presence
US7660851B2 (en) 2005-07-06 2010-02-09 Microsoft Corporation Meetings near me
PT1907374E (pt) 2005-07-26 2012-11-05 Glaxo Group Ltd Derivados de benzilpiperazina úteis para o tratamento de doenças gastrointestinais
US7576106B2 (en) 2005-10-11 2009-08-18 Chemocentryx, Inc. Piperidine derivatives and methods of use
US8069208B2 (en) 2006-04-21 2011-11-29 Microsoft Corporation Peer-to-peer buddy request and response
US8086842B2 (en) 2006-04-21 2011-12-27 Microsoft Corporation Peer-to-peer contact exchange
US8586571B2 (en) * 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2010077915A1 (en) * 2008-12-17 2010-07-08 Forest Laboratories Holdings Limited Novel compounds useful as cc chemokine receptor ligands
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
ATE308985T1 (de) * 1999-05-18 2005-11-15 Teijin Ltd Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
MXPA04000737A (es) * 2001-07-24 2004-07-08 Richter Gedeon Vegyeszet Derivados de piperidina como antagonistas receptores de nmda.

Also Published As

Publication number Publication date
ZA200500067B (en) 2005-11-02
IL166010A0 (en) 2006-01-15
AU2003242941A1 (en) 2004-02-09
JP2005537279A (ja) 2005-12-08
MA27326A1 (fr) 2005-05-02
PE20040666A1 (es) 2004-09-25
ECSP055547A (es) 2005-03-10
IS7614A (is) 2004-12-23
TNSN05014A1 (fr) 2007-05-14
MXPA05000380A (es) 2005-03-31
KR20050021497A (ko) 2005-03-07
WO2004009550A1 (en) 2004-01-29
US20040063759A1 (en) 2004-04-01
CA2492651A1 (en) 2004-01-29
EP1534677A1 (en) 2005-06-01
BR0312946A (pt) 2005-07-12
TW200402416A (en) 2004-02-16
OA12885A (en) 2006-09-15
CN1668592A (zh) 2005-09-14
AR040583A1 (es) 2005-04-13
HN2003000222A (es) 2004-11-23
AP2005003200A0 (en) 2005-03-31
PA8575901A1 (es) 2004-07-20

Similar Documents

Publication Publication Date Title
ECSP055547A (es) Derivados de piperidina novedosos
ECSP055548A (es) Derivados de piperidina biciclicos como antagonistas del receptor quimioquinas ccr1
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
ATE430152T1 (de) Aryl-substituierte diazabicycloalkane als nikotinische acetylcholinagonisten
CR9124A (es) 1-alquinil-2-ariloxialquilamidas y su uso como fungicidas
ATE470662T1 (de) Piperazinylpyrazinverbindungen als agonisten oder antagonisten am serotonin-5ht-2-rezeptor
IS6855A (is) Benzamidazol og Pyrimidazol afleiður sem tengihópar við GABA viðtaka
ATE360627T1 (de) Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
NO20061978L (no) Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon
ECSP045255A (es) Cumarinas utiles como biomarcadores
UY3441Q (es) Cepillo de dientes
ES2141133T3 (es) Morfolina y tiomorfolina como antagonistas de receptores de taquiquininas.
ATE541843T1 (de) 2-acylamino-4-phenylthiazolderivate, ihre herstellung und anwendung als chemokin antagonisten
NO20083582L (no) Pyridin-2-karboksamide derivater
BRPI0409367A (pt) derivados de piperidina inibidores de renina
CY1108457T1 (el) Παραγωγα ξανθινης ως ανταγωνισται υποδοχεως α2β αδενοσινης
DE60319813D1 (de) 1-(4-piperidinyl)benzimidazole als histamin h3 antagonisten
GB0426313D0 (en) Therapeutic agents
NO20052866L (no) Imidazokinolinderivater som adenosin A3 reseptorligander
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
GT200200095A (es) Nuevos derivados de acido sulfonico
DOP2003000656A (es) Derivados de piperidina novedosos
DOP2003000668A (es) Nuevos derivados de piperidina
ATE390427T1 (de) Diazabicylononan - und decanderivate und ihre verwendung als opioid-rezeptorligande
ATE495168T1 (de) Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150427